Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep 11:3:164.
doi: 10.3389/fphar.2012.00164. eCollection 2012.

The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth

Paolo Luraghi  1 , Florian Schelter, Achim Krüger, Carla Boccaccio
Affiliations

The MET Oncogene as a Therapeutical Target in Cancer Invasive Growth

Paolo Luraghi et al. Front Pharmacol. .

Abstract

The MET proto-oncogene, encoding the tyrosine kinase receptor for Hepatocyte Growth Factor (HGF) regulates invasive growth, a genetic program that associates control of cell proliferation with invasion of the extracellular matrix and protection from apoptosis. Physiologically, invasive growth takes place during embryonic development, and, in post-natal life, in wound healing and regeneration of several tissues. The MET oncogene is overexpressed and/or genetically mutated in many tumors, thereby sustaining pathological invasive growth, a prerequisite for metastasis. MET is the subject of intense research as a target for small molecule kinase inhibitors and, together with its ligand HGF, for inhibitory antibodies. The tight interplay of MET with the protease network has unveiled mechanisms to be exploited to achieve effective inhibition of invasive growth.

Keywords: MET oncogene; antibody; invasion; metastasis; microenvironment; proteases; small molecule kinase inhibitors; targeted therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic representation of the receptor tyrosine kinase encoded by the MET oncogene, its ligand HGF, and the main experimental drugs against the receptor or the ligand currently under investigation (engineered MET/HGF antagonists, anti-HGF antibodies, anti-Met antibodies, small-molecule Met inhibitors). The α and β chains of both receptor and ligand are represented. In the receptor, the aminoacidic residues undergoing phosphorylation during signal activation are also indicated. For explanation of the specific domain functions, mechanisms of ligand-receptor interaction, and mechanism of action of experimental drugs, see text.
See this image and copyright information in PMC

References

    1. Amour A., Knight C. G., Webster A., Slocombe P. M., Stephens P. E., Knauper V., Docherty A. J., Murphy G. (2000). The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett. 473, 275–279 10.1016/S0014-5793(00)01528-3 - DOI - PubMed
    1. Amour A., Slocombe P. M., Webster A., Butler M., Knight C. G., Smith B. J., Stephens P. E., Shelley C., Hutton M., Knauper V., Docherty A. J., Murphy G. (1998). TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 435, 39–44 10.1016/S0014-5793(98)01031-X - DOI - PubMed
    1. Basilico C., Arnesano A., Galluzzo M., Comoglio P. M., Michieli P. (2008). A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. J. Biol. Chem. 283, 21267–21277 10.1074/jbc.M800727200 - DOI - PMC - PubMed
    1. Bean J., Brennan C., Shih J. Y., Riely G., Viale A., Wang L., Chitale D., Motoi N., Szoke J., Broderick S., Balak M., Chang W. C., Yu C. J., Gazdar A., Pass H., Rusch V., Gerald W., Huang S. F., Yang P. C., Miller V., Ladanyi M., Yang C. H., Pao W. (2007). MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl. Acad. Sci. U.S.A. 104, 20932–20937 10.1073/pnas.0710370104 - DOI - PMC - PubMed
    1. Birchmeier C., Gherardi E. (1998). Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol. 8, 404–410 10.1016/S0962-8924(98)01359-2 - DOI - PubMed